Heteropolyvalent Hybrid Antibodies of Enhanced Discriminatory Power:Applications in Oncology

Cancer Co-Bodies Lab Diagnosis Selectivity

Royal Society of Medicine, 29th November 2007, ‘Cell Signalling and Novel Cancer Therapeutics.' Joint Meeting of the Oncology Section of the Royal Society of Medicine and the British Association of Cancer Research.

There is strong theoretical reason to expect that individually-specific heteropolyvalent binding agents will be required to identify the cancer cells of each individual patient for purposes of diagnosis and treatment, and agents made with flexible nucleic acid linkers offer yet further advantages.